U.S. pharma executives expect deals to pick up after tax overhaul
SAN FRANCISCO (Reuters) - The Trump administration's tax overhaul should accelerate major acquisitions by drugmakers in 2018 after a slow year for deals in 2017, according to senior executives from some of the largest pharmaceutical manufacturers.
from Reuters: Health News http://reut.rs/2AJNknt
http://bit.ly/2zwRqiM